Open AccessTAp63–miRNA–AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma
Author(s) -
Alejandro Parrales,
Tomoo Iwakuma
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.103
H-Index - 449
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/0008-5472.can-20-1215
Subject(s) - basal cell , medicine , microrna , cancer research , oncology , pathology , biology , gene , biochemistry
Despite increasing incidence rates, prognosis of invasive cutaneous squamous cell carcinoma remains poor, mainly due to lack of reliable molecular markers that can be used for targeted therapy. Through genetic and proteogenomic analyses, Davis and colleagues in this issue of Cancer Research define TAp63 and its downstream target miRNAs, miR-30c-2*, and miR-497 as major players that can suppress progression and metastasis of mouse and human cutaneous squamous cell carcinoma. Mimics of miR-30c-2* or miR-497, as well as pharmacologic inhibition of AURKA, a miR-497 target, suppress tumor growth in xenograft mouse models, proposing the TAp63-miR-30c-2*/miR-497-AURKA axis as a potential therapeutic target. See related article by Davis et al., p. 2484 .